Skip to main content

Table 3 Relationships between gene amplification and molecular subtypes

From: FGFR1 is amplified during the progression of in situto invasive breast carcinoma

  

Subtype

Histologic stage

Gene

Luminal A

Luminal B

HER2-positive

Basal-like

TNNB

Pvaluea

Invasive carcinoma

C-MYC

13/208 (6.3)*,**

15/103 (14.6)**

7/42 (16.7)

14/55 (25.5)*

5/19 (26.3)

< 0.001

 

CCND1

19/205 (9.3)†

37/103 (35.9)†,‡,§

4/42 (9.5)‡

0/55 (0)†

1/18 (5.3)§

< 0.001

 

FGFR1

21/202 (10.4)¶

21/100 (21.0)¶,††,‡‡

3/42 (7.1)††

7/55 (12.7)

0/18 (0)‡‡

0.025

Pure DCIS

C-MYC

6/98 (6.1)

4/24 (16.7)

6/34 (17.6)

1/9 (11.1)

0/8 (0)

0.198

 

CCND1

11/99 (11.1)

6/24 (25.0)

4/35 (11.4)

0/9 (0)

1/8 (12.5)

0.298

 

FGFR1

5/95 (5.3)

4/23 (17.4)

1/33 (3.0)

0/9 (0)

0/8 (0)

0.134

  1. Data presented as n (%). P values calculated using the chi-square test or Fisher's exact test. DCIS, ductal carcinoma in situ; TNNB, triple negative, nonbasal. aBetween molecular subtypes. *P < 0.001, basal-like vs. luminal A. **P = 0.016, luminal B vs. luminal A for C-MYC. †P < 0.001, luminal B vs. luminal A, luminal B vs. basal-like. ‡P = 0.001, luminal B vs. HER2-positive. §P = 0.008, luminal B vs. TNNB for CCND1. ¶P = 0.012, luminal B vs. luminal A. ††P = 0.044, luminal B vs. HER2-positive. ‡‡P = 0.040, luminal B vs. TNNB for FGFR1.